Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Silver Range Resources: A hidden gem in the mining industry (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Insmed Inc INSM

Healthcare Biotechnology
Insmed Incorporated is a global biopharmaceutical company. The Company's first commercial product, ARIKAYCE (amikacin liposome inhalation suspension), is used for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. Its pipeline includes clinical-stage programs... see more

Recent & Breaking News (NDAQ:INSM)

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

PR Newswire February 3, 2023

Analysts and Executives Converge February 2nd at the 30th Annual Emerald Groundhog Day Investment Forum

Business Wire January 26, 2023

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

PR Newswire January 20, 2023

Insmed Provides Business Updates and Near-Term Strategic Outlook at 41st Annual J.P. Morgan Healthcare Conference

PR Newswire January 6, 2023

Insmed To Present at the 41st Annual J.P. Morgan Healthcare Conference

PR Newswire January 3, 2023

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

PR Newswire December 6, 2022

Insmed To Present at the Nasdaq 47th Investor Conference

PR Newswire November 30, 2022

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

PR Newswire November 4, 2022

Insmed To Present at Three November Conferences

PR Newswire November 1, 2022

Insmed Ranks No. 1 on Science's 2022 Top Biopharma Employers List

PR Newswire October 27, 2022

Insmed Reports Third Quarter 2022 Financial Results and Provides Business Update

PR Newswire October 27, 2022

Insmed Announces Strategic Financings Totaling $775 Million

PR Newswire October 19, 2022

Insmed to Host Third Quarter 2022 Financial Results Conference Call on Thursday, October 27, 2022

PR Newswire October 13, 2022

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

PR Newswire October 7, 2022

Insmed Holds Inaugural Global Day of Good - A Company-Wide Day of Service

PR Newswire October 6, 2022

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

PR Newswire September 7, 2022

Insmed To Present at Two September Conferences

PR Newswire September 6, 2022

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

PR Newswire August 5, 2022

Insmed Reports Second Quarter 2022 Financial Results and Provides Business Update

PR Newswire August 4, 2022

Insmed to Host Second Quarter 2022 Financial Results Conference Call on Thursday, August 4, 2022

PR Newswire July 21, 2022